“We are pleased with the outcome of the National Cancer Institute-led Phase 2 triple combination trial of PDS0101, PDS01ADC and an investigational immune checkpoint ihnibitor. The data show that 75% of immune checkpoint inhibitor-naive patients remain alive at three years, and the 12-month overall survival rate in the ICI-resistant patients is 72%,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. “Furthermore, the triple combination continues to be well tolerated, with only 4% of patients reported to have Grade 4 treatment-related adverse events.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PDSB:
- PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
- PDS Biotechnology announces updated survival data from Phase 2 trial of PDS0101
- PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
- PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
- Pds Biotechnology (PDSB) Q3 Earnings Cheat Sheet
